Is Protagonist Therapeutics, Inc. (PTGX) a Buy, Sell, or Hold?
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$131.27 USD
$1.38 (1.06%)
- Volume
- 578.37K
- Average Volume
- 722.65K
- Market Capitalization
- $8.44B
- P/E Ratio
- -72.85
- Dividend Yield
- 0.00%
- Price Target
- $121.00
- Year High
- $141.10
- Year Low
- $50.49
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $17.76
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Dinesh V. Patel |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | PTGX |
| CUSIP | 74366E102 |
| CIK | 0001377121 |
| Web | https://www.protagonist-inc.com |
| Phone | 510 474 0170 |
| Currency | USD |
| Employees | 132 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 17.76 |
| Quick Ratio | 17.76 |
| Cash Ratio | 5.61 |
Sales & Book Value
| Annual Sales | $46.02M |
| Price / Sales | 113.99 |
| Cash Flow | -1.79 |
| Price / Cash Flow | -72.59 |
| Price / Book | 13.03 |
Price Target and Rating
| Average Stock Price Forecast | $121.00 |
| High Stock Price Forecast | $151.00 |
| Low Stock Price Forecast | $110.00 |
| Forecast Upside/Downside | 8.49% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 26 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.05 |
| Trailing P/E Ratio | -72.85 |
| PEG Ratio | 0.20 |
| P/E Growth | 0.20 |
| Net Income | $-130.15M |
| Net Margin | -154.88% |
| Pretax Margin | -155.78% |
| Return on Equity | -17.76% |
| Return on Assets | -16.45% |
Financials Score
| AltmanZ Score | 118.99 |
| Piotroski Score | 1.00 |
| Working Capital | 578.91M |
| Total Assets | 697.46M |
| Ebit | -115.38M |
| Market Cap | 8.35B |
| Total Liabilities | 41.99M |
Poll Results
About Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 recep ... tor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Best Momentum Stocks to Buy for July 13th
2026-07-13 11:01:12
SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 2026.
New Strong Buy Stocks for July 13th
2026-07-13 04:26:03
FOX, LION, EDRY, PTGX and SPH have been added to the Zacks Rank #1 (Strong Buy) List on July 13th, 2026.
New Strong Buy Stocks for July 9th
2026-07-09 05:56:06
PTGX, DHX, COOK, XYZ and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026.
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?
2026-07-08 11:30:13
Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
2026-07-07 12:15:34
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
Protagonist Therapeutics Reports Granting of Inducement Awards
2026-07-01 16:05:00
NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
Protagonist Therapeutics Reports Granting of Inducement Awards
2026-06-16 16:00:00
NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal
2026-06-13 08:46:00
Protagonist Therapeutics (PTGX) has transitioned from binary clinical risk to execution risk, leveraging major pharma partners for commercialization without heavy infrastructure costs. ICOTYDE's FDA approval and rusfertide's Priority Review position PTGX for milestone payments, high-margin royalties, and a capital-light revenue model. PTGX maintains a strong balance sheet with $620M+ cash, a funding runway through 2028, and episodic profitability, reducing financing risk.
Frequently Asked Questions
-
What is the current Protagonist Therapeutics, Inc. (PTGX) stock price?
-
Protagonist Therapeutics, Inc.(NASDAQ:PTGX) stock price is $131.27 in the last trading session. During the trading session, PTGX stock reached the peak price of $141.1 while $50.485 was the lowest point it dropped to. The percentage change in PTGX stock occurred in the recent session was 1.06% while the dollar amount for the price change in PTGX stock was $1.38.
-
PTGX's industry and sector of operation?
-
The NASDAQ listed PTGX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PTGX?
-
Carena Spivey | Executive VP & Chief Human Resources Officer
Arturo Molina FACP | Chief Medical Officer
Ashok Bhandari | EVP & Chief Discovery Officer
Dinesh V. Patel | Chief Executive Officer, President, Secretary & Director
Newman Yeilding | Executive Vice President, Chief Scientific Officer -
How many employees does PTGX have?
-
Number of PTGX employees currently stands at 132. PTGX operates from 7707 Gateway Boulevard, Newark, CA 94560-1160, US.
-
Link for PTGX official website?
-
Official Website of PTGX is: https://www.protagonist-inc.com
-
How do I contact PTGX?
-
PTGX could be contacted at phone #510 474 0170 and can also be accessed through its website. PTGX operates from 7707 Gateway Boulevard, Newark, CA 94560-1160, US.
-
How many shares of PTGX are traded daily?
-
The average number of PTGX shares traded daily for last 3 months was 722.65K.
-
What is the market cap of PTGX currently?
-
The market value of PTGX currently stands at $8.44B with its latest stock price at $131.27